Last update March 23, 2021
An organosulfur compound used as a solvent in industry and in medicine as an excipient in order to increase the percutaneous absorption of other substances (Marren 2011, Turnbull 1969, Baker 1968).
Medically it is used, without clear evidence of efficacy (Brien 2011), as topical, cutaneous and intravesical antalgic anti-inflammatory agents (Rawls 2017).
It is metabolised by oxidation to dimethyl sulfone
In industrial management there are no established TLVs. It causes irritation of the eyes, skin and mucous membranes (PanReac 2017, INSHT 2010).
It is eliminated via the skin and breathing, producing a garlic-like odour.
Since the last update date we have not found published data on its excretion in breastmilk.
Following dermal or bladder application, absorption through the skin or mucous membranes is high and rapid so its excretion in milk is likely.
With regard to occupational risks for breastfeeding mothers (INSHT 2017 and 2008, EC Regulation 2008), the risk phrases (formerly R phrases, currently H-phrases for Hazard) or of precautionary (P-phrases) that should appear on a product’s safety data sheet are only two:
- H362 (ant. R64): "It may harm children who are breastfed"
- P263: "Avoid contact during pregnancy and breastfeeding”.
Another three phrases that should be considered during breastfeeding are related to the carcinogenic, mutagenic or cumulative effects of a product:
- H351 (ant. R40): "Possible carcinogenic effects"
- H371 (ant. R68): "Possibility of irreversible effects"
- H373 (ant. R33) : "Danger of cumulative effects”
Based on the absence of these phrases in the Dimethyl sulfoxide Safety Data Sheet (INSHT 2010, Acofarma 2010), it would not be necessary to remove the breastfeeding mother from her workplace, it would be enough for the company to meet the legal requirements regarding the maximum levels of environmental exposure and for the employee to follow recommended rules of caution (gloves, hand and face washing, change of clothes, etc.) (PanReac 2017, INSHT 2010, Acofarma 2010).
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM